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Abstract 
O-GlcNAc transferase (OGT) is overexpressed in aggressive prostate cancer. OGT modifies intra-cellular 
proteins via single sugar conjugation (O-GlcNAcylation) to alter their activity. We recently discovered the first 
fast-acting OGT inhibitor OSMI-2. Here, we probe the stability and function of the chromatin O-GlcNAc and 
identify transcription factors that coordinate with OGT to promote proliferation of prostate cancer cells. 
Methods: Chromatin immunoprecipitation (ChIP) coupled to sequencing (seq), formaldehyde-assisted 
isolation of regulatory elements, RNA-seq and reverse-phase protein arrays (RPPA) were used to study the 
importance of OGT for chromatin structure and transcription. Mass spectrometry, western blot, RT-qPCR, 
cell cycle analysis and viability assays were used to establish the role of OGT for MYC-related processes. 
Prostate cancer patient data profiled for both mRNA and protein levels were used to validate findings. 
Results: We show for the first time that OGT inhibition leads to a rapid loss of O-GlcNAc chromatin mark. 
O-GlcNAc ChIP-seq regions overlap with super-enhancers (SE) and MYC binding sites. OGT inhibition leads to 
down-regulation of SE-dependent genes. We establish the first O-GlcNAc chromatin consensus motif, which 
we use as a bait for mass spectrometry. By combining the proteomic data from oligonucleotide enrichment 
with O-GlcNAc and MYC ChIP-mass spectrometry, we identify host cell factor 1 (HCF-1) as an interaction 
partner of MYC. Inhibition of OGT disrupts this interaction and compromises MYC’s ability to confer 
androgen-independent proliferation to prostate cancer cells. We show that OGT is required for 
MYC-mediated stabilization of mitotic proteins, including Cyclin B1, and/or the increased translation of their 
coding transcripts. This implies that increased expression of mRNA is not always required to achieve increased 
protein expression and confer aggressive phenotype. Indeed, high expression of Cyclin B1 protein has strong 
predictive value in prostate cancer patients (p=0.000014) while mRNA does not. 
Conclusions: OGT promotes SE-dependent gene expression. OGT activity is required for the interaction 
between MYC and HCF-1 and expression of MYC-regulated mitotic proteins. These features render OGT 
essential for the androgen-independent, MYC-driven proliferation of prostate cancer cells. 
Androgen-independency is the major mechanism of prostate cancer progression, and our study identifies OGT 
as an essential mediator in this process. 
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Introduction 
It is well known that metabolites can affect cell 
fate by regulating transcription. This was initially 
established for the lactose-regulated lac operon in 
bacteria and the galactose-regulated gal regulome in 
yeast [1]. Metabolite-dependent regulation of 
transcription in multicellular organisms has also been 
established, and as an example, sterol synthesis is 
regulated by sterol regulatory element-binding 
protein 1 (SREBP1) [2]. In the absence of sterols, 
SREBP1 is cleaved, and this cleavage generates an 
active nuclear transcription factor that promotes 
expression of genes involved in sterol biosynthesis. 
 Altered metabolite levels are a prominent 
feature of cancer cells/tumors and have been directly 
linked to their ability to proliferate rapidly [3, 4]. One 
of the most prominent features of cancer cells is the 
‘Warburg effect’, where cells exhibit increased glucose 
uptake and fermentation of glucose to lactate even in 
the presence of fully functional mitochondria and 
oxygen. Further underlining the increased appetite of 
cancer cells for glucose, this metabolite is frequently 
used as a tracer to localize tumors and follow 
response to therapy using PET-imaging [5]. In the case 
of prostate cancer, which is lipogenic, tumors can also 
be traced using 11C-Acetate [6, 7]. Cancer cells adapt to 
metabolite availability through transcriptional and 
translational regulation; however, post-translational 
modifications provide a rapid response to 
extracellular stimuli. 
O-GlcNAc transferase (OGT), the sole enzyme in 
the human genome that modifies target protein serine 
and threonine residues with a single O-GlcNAc sugar, 
is a major metabolic integration point in cells [8]. 
OGT’s substrate, UDP-GlcNAc, is produced via the 
hexosamine biosynthetic pathway (HBP), which uses 
glucose, glutamine, acetyl-CoA and UTP as building 
blocks [9]. Flux through the HBP increases in response 
to glucose, which leads to increased O-GlcNAcylation 
of nuclear proteins [10]. Among the most prominent 
O-GlcNAc modified factors is the C-terminal domain 
of RNA-Polymerase II, which regulates pre-initiation 
complex formation [11-13]. Increased expression of 
OGT has been demonstrated in most cancers, 
including prostate cancer, where high 
protein-O-GlcNAc levels have been shown to 
correlate with poor clinical outcome [14-16]. 
Prostate cancer is the most common male cancer, 
and the androgen receptor (AR) is the major driver 
and drug target in this disease [17, 18]. The AR is 
typically expressed at high levels in prostate cancer 
and positively regulates the HBP [18-20]. One 
mechanism by which increased HBP flux, and 
especially OGT activity, benefits cancer cells, is 
through stabilization of pro-oncogenic proteins such 
as MYC [14, 21, 22]. 
MYC is a transcription factor that is essential for 
the proliferation of most cancer cells [23]. The protein 
binds to MAX to form a complex, which, in general, 
positively regulates transcription [24]. MYC binds to a 
DNA sequence-motif known as the E-box [25]. 
E-boxes occur every 4kb in the human genome, but 
MYC binds only to the subset of these sites that are 
non-methylated and accessible [26]. When MYC levels 
increase, as they do in tumors, there is increased 
binding to lower affinity E-boxes [27]. Increased MYC 
expression leads to enhanced expression of the 
cell-specific transcriptional program rather than 
activation of new genes [28, 29]. 
OGT and MYC work together to enhance cancer 
cell proliferation [14, 21, 22]. Inhibition of OGT 
activity down-regulates MYC in prostate cancer cells 
[30], while increased glucose levels lead to 
OGT-mediated stabilization of MYC in liver cancer 
cells [21]. Cells infected with human papillomavirus, 
the causative agent in genital cancers, have high levels 
of OGT, which promotes MYC stability [31]. In 
activated T cells, MYC affects O-GlcNAcylation 
through regulation of glucose and glutamine 
transport [22]. These data highlight the complex 
interplay between OGT and MYC in cancer cells. It is 
currently not known if OGT affects the 
MYC-dependent cellular program. 
Here, we show that inhibition of OGT activity 
disrupts the interaction between MYC and HCF-1, a 
known transcriptional co-activator. Inhibition of OGT 
enhances MYC’s ability to suppress transcription of 
certain cell cycle genes and at the same time enhances 
the expression of genes involved in the degradation of 
cell cycle proteins. We show that OGT is required for 
MYC-mediated stabilization of proteins involved in 
mitosis. MYC’s dependency on OGT becomes most 
evident during androgen-deprivation, a condition in 
which overexpression of MYC can drive proliferation. 
In addition, we show that OGT regulates 
super-enhancer-dependent transcription through 
chromatin compaction. Our study is the first one to 
promote combination of OGT inhibitor with 
AR-targeted therapies as a strategy for 
castration-resistant prostate cancer. 
Methods 
Cell culture conditions and treatments 
LNCaP and PC3 cell lines were obtained from 
the ATCC and maintained according to ATCC 
guidelines. LNCaP and PC3 cells were grown in RPMI 
media supplemented with 10% FBS. For hormone 
starvation, cells were cultured in phenol red-free 
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RMPI supplemented with 10% charcoal-stripped FBS. 
LNCaP-MYC cells were maintained as described 
previously [32] and MYC overexpression was induced 
using 2μg/ml doxycycline (Sigma). Tamoxifen- 
inducible OGT knockout mouse embryonic fibroblast 
(MEF) cell line was obtained from Dr. Natasha 
Zachara at the CardioPEG CoreC4 (NHLBI P01 
HL107153) at Johns Hopkins University School of 
Medicine [33]. Cell viability was assessed using 
CellTiterGlo-reagent (CTG, Promega) according to the 
manufacturer's instructions. Each CTG-experiment 
was done using 384-well plates and consisted of at 
least 3 technical and 3 biological replicates. PUGNAc, 
Thiamet-G, cOmplete™ EDTA-free Protease Inhibitor 
Cocktail and PhosSTOP™ were purchased from 
Sigma. (Z)-4-Hydroxytamoxifen was obtained from 
Abcam (ab141943). The second-generation OGT 
inhibitors OSMI-2 and OSMI-4 have been described 
[34]. Cell cycle distribution was analyzed using the 
Propidium Iodide Flow Cytometry Kit (Abcam, 
ab139418) and the BD FACSCanto instrument (BD 
Biosciences). Transfections for siRNA experiments 
were performed using RNAiMax reagent (Sigma), 
and OGT targeting siRNAs were obtained from Life 
Technologies (s16094 and s16095). 
Preparation of cell lysates 
Preparation of cell lysates for western blotting 
(WB) was done as previously described [19]. 
Antibodies were obtained from Cell Signaling 
Technology: MYC #5605, OGT #24083, CDK1 #9116, 
Cyclin B1 #4138, PLK1 #4513, p-H3ser10 #9701, H3 
#4499, p-S2/5-Pol II #4735, GSK3β #12456; from 
Sigma: OGA #HPA036141; from Abcam: RL2 
#ab2739, Actin #ab49900 and from Bethyl 
Laboratories: HCF-1 #A301-399a. Reverse Phase 
Protein Array (RPPA) samples were prepared using 
the same protocol as for WB, and RPPA was 
purchased as a service from MD Anderson. Signal 
from 302 antibodies was detected. 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was 
performed from ~2x107 cells by first cross-linking 
cells with 1% para-formaldehyde (pFa) at room 
temperature for 10 minutes. PFa was quenched by 
addition of 125mM glycine for 10 minutes, and cells 
were washed twice in ice-cold PBS. Next, cells were 
solubilized into ChIP lysis buffer (0.1% SDS, 1% 
Triton X-100, 150mM NaCl, 1mM EDTA, 20mM 
Tris-HCl pH8.0, protease inhibitor, phosphatase 
inhibitor and 50µM PUGNAc (the last three added 
fresh)), and samples were sonicated using Bioruptor 
(Diagenode) to obtain DNA fragments of 200-500 base 
pairs in length (confirmed by agarose gel analysis for 
every experiment). After sonication, samples were 
centrifuged, and the supernatant was used for ChIP. 
Antibodies for ChIP were: RL2 #ab2739 (Abcam), 
MYC AF3696 (R&D systems) and HCF-1 #A301-399a 
(Bethyl Laboratories). ChIP was performed overnight 
at +4˚C, and beads were washed as follows: 2x in 
wash buffer 1 (0.1% SDS, 0.1% Na-deoxycholate, 1% 
Triton X-100, 0.15M NaCl, 1mM EDTA, 20mM HEPES 
pH8.0), 1x in wash buffer 2 (0.1% SDS, 0.1% 
Na-deoxycholate, 1% Triton X-100, 0.5M NaCl, 1mM 
EDTA, 20mM HEPES pH8.0), 1x in wash buffer 3 
(0.25M LiCl, 0.5% Na-deoxycholate, 0.5% NP-40, 1mM 
EDTA, 20mM HEPES pH8.0) and 2x in wash buffer 4 
(10mM EDTA, 20mM HEPES pH8.0). After this, DNA 
was extracted using phenol-chloroform extraction and 
used for sequencing or qPCR. RNA for RT-qPCR and 
RNA-seq was isolated using an illustraMiniSpin kit 
(GE Healthcare) according to the manufacturer's 
instructions, and cDNA was synthesized using a 
qScript cDNA Synthesis Kit (Quanta Biosciences). 
Primers for ChIP-qPCR and RT-qPCR are provided in 
Supplementary Table. 
Formalin-assisted isolation of regulatory 
elements 
One million LNCaP cells were plated for 3 days 
and half of media was replaced to fresh media when 
cells were treated with DMSO or 20µM OSMI-4 for 24 
hours. Cells were fixed by adding formaldehyde in 
1% final concentration for 10 minutes at room 
temperature and fixation was stopped by addition of 
125mM glycine (final) for 5 minutes at room 
temperature. Plates were washed with ice cold PBS, 
cells pelleted by centrifugation (1000rpm, 10 minutes) 
and lysed in 0.5% SDS, 0.5% TritonX 100, 150mM 
NaCl, 10mM EDTA, 50mM Tris-HCl pH8.0 containing 
1X protease inhibitor. Samples were sonicated using 
Bioruptor. Input sample was taken and the rest of the 
sample was subjected to three subsequent 
phenol:chloroform:isoamyl alcohol (25:24:1) 
extractions to isolate protein-free DNA in the aqueous 
phase using columns (#2302830, 5Prime, QuantaBio). 
All the samples (including input) were treated with 
proteinase K for 1 hour at +55˚C, DNA de-crosslinked 
at +65˚C for 4 hours and purified using standard 
phenol-chloroform extraction. qPCR was used to 
evaluate chromatin compaction relative to input. 
Analysis of the ChIP-seq data 
Summary of read counts for ChIP-seq are 
provided in Supplementary Table. The raw reads 
from previously published studies and generated for 
this study (ChIP-seq of MYC and O-GlcNAc) were 
mapped with novoalign (http://www.novocraft 
.com) to the human reference genome (build hg19) 
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with default parameters. Only reads with q>20 and a 
maximum of 5 read duplicates per genomic location 
were allowed by our filtering. Peak detection (i.e., 
binding site detection) for both ChIP- and DHS–seq 
was performed with MACS1.4 [35] with default 
parameters. Overlaps between datasets were 
performed with bedtools v2.25.0 [36]. Read 
distribution analysis around center feature peaks was 
performed as previously described [37] or using 
bwtool 1.0 - Data operations on bigWig files [38]. To 
assess the presence of motifs of transcription factors 
(TFs) in the O-GlcNAc dataset, we looked for 
overrepresented TF motifs. Prediction of TF binding 
was performed using “findMotifsGenome.pl” with 
motif lengths from 6 to 30 nt, and peaks distribution 
analysis was performed with “annotatePeaks.pl”, 
both parts of the HOMER package [39]. 
Analysis of the RNA-seq data 
RNA-seq raw paired-end reads from different 
lanes were concatenated and trimmed with 
Trimgalore (v.0.4.1). We used Salmon (v0.9.1) [40] to 
quantify the expression of transcripts from UCSC 
human genome (hg19). We run Salmon with default 
parameter and corrected input data for fragment-level 
GC biases using parameter --gcBias. We performed 
differential expression analysis using DEBrowser [41] 
with DESeq2 [42] by uploading the read counts 
retrieved from Salmon. Principal component analysis 
of RNA-seq data was plotted using the function 
plotPCA, which is included within the DESeq2 
package. The biological replicate samples showed 
strong correlation for each treatment (Supplementary 
Fig. 9). 
Data availability 
The ChIP-seq and RNA-seq data reported in this 
manuscript has been deposited in the NCBI GEO data 
repository (GSE121474). 
RIME and oligo pulldown  
RIME was performed as previously described 
[43]. For oligo pulldown, ~2x107 cells were used. All 
the steps were performed at 4˚C unless otherwise 
mentioned. Cells were washed with PBS and collected 
by centrifugation. Next, cells were solubilized into 
HKMG-buffer (10mM HEPES pH7.5, 100mM KCl, 
5mM MgCl2, 10% glycerol, 0.5% NP-40, 1mM DTT, 
protease inhibitor, phosphatase inhibitor and 50µM 
PUGNAc (the last four added fresh) and sonicated 
using Bioruptor (Diagenode). Samples were 
centrifuged full speed for 10 minutes and the 
supernatant collected. 
Biotinylated oligos were prepared by mixing 
30µL of sense and anti-sense sequences (30mg per ml) 
with 6.6µL of 10X PCR buffer (100mM TRIS-HCl 
pH8.0, 15mM MgCl2). Next, this mixture was heated 
to 100˚C for 5 minutes and allowed to cool down to 
room temperature on a heat block. 
One vial of Streptavidin MagneSphere® 
Paramagnetic Particles (Z5481, Promega) was 
prepared for each sample by washing three times with 
HKMG-buffer, and suspended into 100µL of 
HKMG-buffer (50µL for pre-clearing of samples, 50µL 
used to bind to oligo). 10µL of annealed oligos were 
rotated with 50µL of beads for 15 minutes in room 
temperature, washed 3 times with HKMG-buffer and 
stored on ice until use. 
Cell extracts were pre-cleared with 50µL of beads 
for 1 hour. After this, oligo-bead complexes were 
added to extract and incubation was continued 
overnight. The next day, beads were washed five 
times with HKMG-buffer and stored at -80˚C until 
mass spectrometry analysis. 
Liquid chromatography-mass spectrometry 
(LC-MS) 
The beads from RIME and oligo pulldown were 
incubated with 2 µg trypsin GOLD (Promega, 
Madison, WI, USA) in 50 µl 25 mM ammonium 
bicarbonate pH 7.8 for 16 h at 37°C. The resulting 
peptides were purified using a 10 µl OMIX C18-SPE 
pipette tip (Agilent, Santa Clara, CA, USA), and dried 
using a Speed Vac concentrator (Concentrator Plus, 
Eppendorf, Hamburg, Germany). Subsequently, the 
tryptic peptides were dissolved in 10 µl 0.1% formic 
acid/2% acetonitrile and 5 µl samples were analyzed 
using an Ultimate 3000 RSLCnano-UHPLC system 
connected to a Q Exactive mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany) equipped with a 
nano-electrospray ion source. For liquid 
chromatography separation, an Acclaim PepMap 100 
column (C18, 2 µm beads, 100 Å, 75 μm inner 
diameter, 50 cm length) (Dionex, Sunnyvale CA, USA) 
was used. A flow rate of 300 nL/min was employed 
with a solvent gradient of 4-35% B over 60 min. 
Solvent A was 0.1% formic acid and solvent B was 
0.1% formic acid/90% acetonitrile. The mass 
spectrometer was operated in the data-dependent 
mode to automatically switch between MS and 
MS/MS acquisition. Survey full scan MS spectra 
(from m/z 400 to 2,000) were acquired with the 
resolution R = 70,000 at m/z 200, after accumulation 
to a target of 1x106. The maximum allowed ion 
accumulation times were 60 ms. The method used 
allowed sequential isolation of up to the ten most 
intense ions, depending on signal intensity (intensity 
threshold 1.7x104), for fragmentation using 
higher-energy collisional induced dissociation (HCD) 
at a target value of 1x105 charges, NCE 28, and a 
resolution R = 17,500. Target ions already selected for 
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MS/MS were dynamically excluded for 30 sec. The 
isolation window was m/z = 2 without offset. For 
accurate mass measurements, the lock mass option 
was enabled in MS mode. 
Data were acquired using Xcalibur v2.5.5 and 
raw files were processed to generate a peak list in 
Mascot generic format (*.mgf) using ProteoWizard 
release version 3.0.331. Database searches for trypsin 
fragments were performed using Mascot in-house 
version 2.4.0 to search the SwissProt database 
(Human, 20279 proteins), allowing a maximum of one 
missed trypsin cleavage site for any given peptide, 
fragment ion mass tolerance of 0.05 Da, parent ion 
tolerance of 10 ppm, with oxidation of methionines 
and acetylation of the protein N-terminus as variable 
modifications. Scaffold (version Scaffold_4.4.8, 
Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein 
identifications. Peptide identifications were accepted 
if they could be established at greater than 95.0% 
probability by the Scaffold Local FDR algorithm. 
Protein identifications were accepted if they could be 
established at greater than 99.0% probability and 
contained at least two identified peptides. 
Results 
Global chromatin O-GlcNAc mark is sensitive 
to OGT inhibition 
In order to probe the stability of the O-GlcNAc 
chromatin mark, we utilized a recently reported 
fast-acting OGT inhibitor OSMI-2 [34] and a specific 
antibody recognizing the O-GlcNAc epitope [13, 44]. 
First, we used western blotting to assess the effects of 
OSMI-2 on the total O-GlcNAc levels in AR-positive 
(LNCaP) and AR-negative (PC3) prostate cancer cell 
line after 4 hours of treatment (Fig. 1A). OSMI-2 more 
efficiently decreased total-O-GlcNAc in PC3 cells, 
which was therefore selected to probe the stability of 
the O-GlcNAc mark on chromatin. We performed a 
biological triplicate ChIP-seq experiment in the 
presence and absence of OSMI-2 and detected 8,906 
peaks in PC3 cells (Fig. 1B). Strikingly, 4 hours 
treatment with OSMI-2 decreased the number of 
O-GlcNAc peaks by 70%, which shows that this 
chromatin mark is remarkably un-stable and further 
validates that it is installed by OGT (Fig. 1B). Strong 
enrichment of the chromatin-bound O-GlcNAc was 
quantitatively and reproducibly lost upon OSMI-2 
treatment, as exemplified using the promoter for the 
MAX gene (Fig. 1C). We validated the O-GlcNAc 
ChIP-seq data using OGT inhibition and genetic 
depletion of OGT (Supplementary Fig. 1). This is the 
first study to report that O-GlcNAc chromatin mark is 
rapidly lost when OGT activity is inhibited. 
O-GlcNAc chromatin mark has been reported to 
localize to transcription start sites (TSS) [13, 44]. We 
therefore evaluated the peak distribution of 
O-GlcNAc in DMSO and OSMI-2 treated cells. We 
observed a sharp single peak for DMSO-treated cells, 
while OSMI-2 treatment led to a remarkable 
re-distribution of the single O-GlcNAc peak into two 
separate peaks (Fig. 1D). Next, we evaluated the peak 
distribution of the peaks that overlap in the DMSO 
and OSMI-2 ChIP-seq. In this case, both conditions 
showed sharp single peak. Despite OGT inhibition, 
we detected these O-GlcNAc marked sites, and 
accordingly, these common sites have the most stable 
O-GlcNAc mark based on the read counts (compare 
DMSO-treated sample in Fig. 1D to 1E). Importantly, 
the strength of the meta-peak was decreased by ~50% 
for the OSMI-2 treatment (Fig. 1E). These data show 
that the O-GlcNAc chromatin mark is dependent on 
high OGT activity. The drastic re-distribution of the 
O-GlcNAc peaks in response to OSMI-2 suggests that 
this modification participates in transcriptional 
regulation. 
 Most prostate cancers are AR-positive [18], and 
we therefore evaluated the conservation of the 
O-GlcNAc chromatin mark localization between 
AR-positive prostate cancer cell line (LNCaP) and PC3 
cells. The majority of the LNCaP O-GlcNAc ChIP-seq 
sites overlapped with the O-GlcNAc sites in PC3 cells 
(70%, Supplementary Fig. 2A). In addition, LNCaP 
O-GlcNAc sites overlapped significantly with 
previously reported single-replicate ChIP-seq studies 
(Fig. 2A). The high degree of conservation between 
cell lines of different origin suggests that O-GlcNAc 
could be a regulator of fundamentally important 
pathways. 
We selected the genes associated with the 
O-GlcNAc chromatin mark in both LNCaP and PC3 
cells and subjected this gene set to pathway 
enrichment analysis to identify candidate 
OGT-regulated pathways in prostate cancer cells. 
Among the top pathways were ‘RNA transport’, 
‘ribosome’, ‘Ubiquitin mediated proteolysis’ and ‘cell cycle’ 
(Supplementary Fig. 2B). Our data identifies a 
mechanism that directly links OGT to biomass 
production and proliferation, in support of models 
proposing OGT as a nutrient sensor [45]. In order to 
better understand the role of chromatin O-GlcNAc 
mark, we moved on to characterize its specific 
localization throughout the genome. 
O-GlcNAc marks transcriptionally active 
chromatin and super-enhancers 
The majority of chromatin-bound O-GlcNAc was 
found in promoters (57%), as previously reported 
(Fig. 2B) [13, 44]. Almost all of the O-GlcNAc sites 
(95%) overlapped with DNase-hypersensitive regions 
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(DHS) and markers of active promoters (h3K4me3 
and h3K27ac) but no overlap was observed with a 
marker of transcriptionally inactive chromatin 
(h3K27me3, Fig. 2C). In addition, 95% of chromatin 
O-GlcNAc overlapped with active transcription 
(RNA-Pol II and nascent RNA). These data are in 
agreement with reports showing that RNA-Pol II CTD 
is O-GlcNAc modified and that O-GlcNAc and 
RNA-Pol II sites overlap [11-13]. Given the prominent 
overlap between O-GlcNAc and RNA-Pol II 
chromatin-bound regions, we evaluated if OGT 
inhibition affects phosphorylation status of RNA 
Pol-II but did not observe prominent effects 
(Supplementary Fig. 3A). These data indicate that 
OSMI-2 does not exert global defect in RNA-Pol II 
activity but could affect expression of certain genes 
driven by a specific class of regulatory elements. 
Super-enhancers (SE) are cell-type specific 
enhancers of highly transcribed genes [46]. We 
assessed if O-GlcNAc mark overlaps with these 
regulatory elements. SEs have been mapped in 
LNCaP cells using the h3K27ac histone modification 
as the surrogate [47]. Most (70%) of the SE-genes were 
associated with the O-GlcNAc mark (Fig. 2D). OGT 
inhibition decreased the expression of CDK1 and 
KLK3, two SE-genes selected for validation (Fig. 2E, F 
and Supplementary Fig. 3B). Targeting OGT has been 
shown to decrease the expression of CDK1, but the 
reason for this is not understood [30]. 
 
 
Figure 1. Global chromatin O-GlcNAc mark is sensitive to OGT inhibition. A) 40µM OSMI-2 treatment rapidly decreases global O-GlcNAc levels as determined 
using western blot after 4 hours of treatment. B) Summary of the PC3 O-GlcNAc ChIP-seq data. Cells were treated for 4 hours with DMSO or 40µM OSMI-2. The data shown 
represents overlap of three biological replicate samples for both DMSO and OSMI-2 treatments. C) OSMI-2 treatment decreases O-GlcNAc peak strength. University of 
California, Santa Cruz (UCSC) Genome Browser view of the Max gene promoter and three biological replicate O-GlcNAc ChIP-seq experiments. D) Distribution of O-GlcNAc 
ChIP-seq reads within ±5kb of O-GlcNAcylated regions within either DMSO or OSMI-2 conditions. Data shown is an average of three biological replicates with SEM. E) 
Distribution of O-GlcNAc ChIP-seq reads within ±5kb of O-GlcNAcylated regions overlapping within DMSO and OSMI-2 conditions. Data shown is an average of three 
biological replicates with SEM. 
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Figure 2. O-GlcNAc chromatin mark overlaps with active promoters and super-enhancers. A) UpSet plot shows the overlap of O-GlcNAc consensus peak-set 
(10,463) with previously reported OGT and O-GlcNAc ChIP-seq datasets (BJAB O-GlcNAc [GSM2295951], HEK OGT [GSE36620], and HEK O-GlcNAc [GSE36620]. B) Peak 
distribution of O-GlcNAc ChIP-seq data reported here with respect to known genomic elements. C) O-GlcNAc consensus overlap with previously published datasets. 
Accession numbers to published datasets: DNase I hypersensitive site (DHS): GSM816637, H3K4me1: GSE73994, H3K27ac: GSE73994, H3K4me3: GSE73994, H3K27me3: 
GSE73994, RNA-Pol II: GSE28126 and Global Run-On Sequencing (GRO-seq); retrieved from Wang et al., 2011 and analyzed according to Chae et al., 2015) [73, 74]. D) Overlap 
of LNCaP O-GlcNAc ChIP-seq marked genes with LNCaP super-enhancers as reported previously [47]. E) The effect of 40µM OSMI-2 (24 hours) on CDK1 and KLK3 mRNA 
expression. The data shown is an average of three biological replicates with SEM. F) The effect of OSMI-4 (24 hours) on CDK1 expression at the protein level. Densitometry was 
used to determine the intensity of the indicated proteins. G) Expression of the CDK1 gene in prostate cancer patient samples. Data was downloaded from 
http://www.betastasis.com/prostate_cancer/taylor_et_al_2010. The mean values with SEM are shown for each group. The significance of the data was evaluated using Student’s 
t-test in comparison to normal samples, ***<0.001. H) Expression of OGT in prostate cancer tumor samples that overexpress CDK1 (n=19) and the rest (n=479). The figure was 
generated using data available through cBioPortal [75, 76]. 
 
O-GlcNAc mark did not always directly overlap 
with SEs (Supplementary Fig. 3C, D), and we 
therefore assessed if OGT activity is important to 
maintain chromatin-accessibility using formaldehyde- 
assisted isolation of regulatory elements (FAIRE). 
OGT inhibition led to chromatin compaction of both 
the CDK1 and KLK3 enhancers (Supplementary Fig. 
3E). In order to position our finding into clinical 
setting, we evaluated the expression pattern of OGT 
and CDK1 in prostate cancer patient samples. CDK1 
expression increases steadily from normal prostate 
tissue to high Gleason Score prostate cancer and 
tumors with high CDK1 expression have significantly 
elevated levels of OGT (Fig. 2G, H). These data imply 
that high OGT activity is important for the expression 
of CDK1 also in vivo. 
To summarize our findings so far, we show for 
the first time that O-GlcNAc chromatin mark is 
associated with SE genes and OGT-activity is 
important for the expression of the genes driven by 
SEs. In addition, O-GlcNAc is enriched on the 
transcriptionally active promoters in prostate cancer 
cells but we do not currently know whether this 
modification is primarily associated with histones or 
transcription factors. 
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MYC co-occupies O-GlcNAc marked 
chromatin sites 
Histone read distributions around chromatin- 
bound O-GlcNAc show that O-GlcNAc sites have the 
typical chromatin structure of a region bound by 
transcription factors (Fig. 3A). To identify candidate 
transcription factors binding to this motif, we 
performed de novo motif discovery using HOMER. 
The top two motifs for O-GlcNAc ChIP-seq were 
similar to the ETS (also known as E26 
transformation-specific) transcription factor ELK4 and 
ELK1 motifs (Fig. 3B). We validated this overlap by 
confirming that 80% of the O-GlcNAc regions overlap 
with the prostate cancer-relevant ETS transcription 
factor, ETV1 (Supplementary Fig. 4A) [18]. However, 
we did not observe prominent overlap between 
O-GlcNAc occupied regions and other transcription 
factors relevant for prostate cancer progression (AR, 
FOXA1 and HOXB13, Supplementary Fig. 4A) [18]. 
OGT has previously been reported to be a critical 
mediator of MYC-dependent transformation [14, 21, 
22]. We therefore performed a MYC ChIP-seq 
experiment and observed that 77% of the MYC 
binding regions overlapped with chromatin-bound 
O-GlcNAc in prostate cancer cells (Fig. 3C). To 
validate the observed overlap, we used a previously 
published MYC ChIP-exo dataset [48]. ChIP-exo 
allows smaller peaks to be detected more readily, 
which leads to a higher number of peaks than the 
conventional ChIP-seq [49]. We observed that ~90% of 
the O-GlcNAc-marked regions overlapped with the 
MYC ChIP-exo peaks (Fig. 3D). O-GlcNAc chromatin 
mark is clearly associated with MYC binding sites but 
we do not yet know how OGT affects MYC function. 
OGT activity is required for MYC-HCF-1 
interaction 
In order to further characterize the 
O-GlcNAc-modified and chromatin-associated 
 
 
Figure 3. Identification of transcription factors that bind to O-GlcNAc marked chromatin. A) Distribution of differently modified histone 3 reads within ±2kb of 
O-GlcNAc peak. B). The top 3 motifs enriched for the O-GlcNAc ChIP-seq data showing similarity with known previously identified transcription factor motifs from published 
datasets. C) O-GlcNAc ChIP-seq consensus overlap with MYC ChIP-seq data reported in this study. D) O-GlcNAc ChIP-seq consensus overlap with MYC ChIP-exo dataset 
reported previously (GSE73994). E) OSMI-2 disrupts interaction between MYC and HCF-1. Immunoprecipitation (IP) of MYC. IgG denotes negative control. MYC was 
overexpressed by addition of doxycycline using the LNCaP-MYC cell line for 4 hours either in the presence or absence of 40µM OSMI-2. Experiment was repeated four times. 
F) Knockout of OGT disrupts the interaction between MYC and HCF-1. Experiment was performed in a mouse embryonic fibroblast cell line that has been genetically 
engineered to enable removal of OGT gene by addition of 0.5µM Tamoxifen (Tam). After two days of DMSO- or Tam-treatments, cell lysates were prepared and used for 
immunoprecipitation. Data shown is representative of two biological replicates. G) Overlap of O-GlcNAc (this study), MYC (this study) and HCF-1 (ENCSR000ECH) ChIP-seq 
data. 
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protein complex that contains MYC, we used mass 
spectrometry. First, we performed RIME (Rapid 
Immunoprecipitation for Mass spectrometry of 
Endogenous proteins) using the same anti-O-GlcNAc 
antibody as we used for ChIP-seq. Second, we 
prepared a biotinylated oligonucleotide of the 
GFY-sequence, which was the third most enriched 
motif for O-GlcNAc ChIP-seq (Fig. 3B). Finally, we 
overlapped these two datasets with MYC RIME and 
identified a single protein, Host Cell Factor 1 (HCF-1; 
also called HCFC1) (Supplementary Table). 
 We confirmed that MYC interacts with HCF-1 in 
prostate cancer cells (Fig. 3E), as previously reported 
using a different model system [50]. HCF-1 is cleaved 
at one of several central repeats, explaining the 
multiple bands observed in the western blot; the N- 
and C-terminal fragments remain associated in cells to 
form the functional protein [51]. Both MYC and 
HCF-1 can be glycosylated by OGT, and we observed 
that a short-term treatment (4 hours) with OGT 
inhibitor OSMI-2 abrogates the interaction between 
the two (Fig. 3E) [30, 52]. Reciprocally, we 
immunoprecipitated HCF-1 and observed that 
OSMI-2 decreases the interaction between HCF-1 and 
MYC (Supplementary Fig. 4B). Next, we used 
siRNAs to knockdown OGT, and observed that this 
decreases the interaction between MYC and HCF-1 
(Supplementary Fig. 4C). In order to confirm that 
OGT is important for the interaction between MYC 
and HCF-1, we used a MEF cell line, in which OGT 
gene can be deleted from the genome by tamoxifen- 
inducible Cre-recombinase [33]. Importantly, OGT 
knockout disrupted the interaction between MYC and 
HCF-1 (Fig. 3F). 
OGT activity might be essential for transcription 
factor complex formation in general, and the 
fast-acting OSMI-2 enabled us to assess this. OSMI-2 
treatment resulted in the loss of interaction between 
MYC and SP1, the first transcription factor reported to 
be O-GlcNAc modified and a known MYC-interaction 
partner (Supplementary Fig. 4D) [53, 54]. On the 
other hand, OSMI-2 did not affect the previously 
reported interaction between AR and HCF-1 
(Supplementary Fig. 4B, E) [55]. This differential 
sensitivity may be important for the integration of 
nutrient-availability to engage with 
proliferative-program (MYC) or maintenance of 
cell-identity (AR). 
Our data shows that the acute OGT inhibition 
affects MYC interaction with partner proteins. In 
support of this, treatment with OSMI-2 led to loss of 
MYC-targets in the O-GlcNAc ChIP-seq data 
(Supplementary Fig. 4F). Over half of the 
MYC-bound chromatin regions are additionally 
marked by O-GlcNAc and HCF-1, further supporting 
the functional relevance of the MYC-HCF-1 
interaction (Fig. 3G). Based on these data, we propose 
that OGT is important for the MYC-dependent 
transcriptional program. 
OGT regulates the MYC-dependent 
transcriptome and proteome 
In order to assess the effect of OGT inhibition on 
MYC-dependent transcription, we used a cell line 
model in which MYC can be induced by the addition 
of doxycycline and performed RNA-seq in the 
presence and absence of OSMI-2. We first confirmed 
that OSMI-2 does not prominently affect 
MYC-induction at the mRNA and protein levels (Fig. 
4A, B). In order to assess if OSMI-2 affects all 
MYC-dependent genes in one way or the other, we 
performed principal component analysis. The effect 
on gene expression was dominated by 
MYC-induction, in agreement with previous reports 
establishing MYC as a strong transcriptional activator 
(Supplementary Fig. 5A) [28, 29]. OSMI-2 had only a 
modest effect, which may be explained by the fact that 
OGT-expression is strongly increased and OGA 
down-regulated in response to OSMI-2 
(Supplementary Fig. 5B). 
Addition of OSMI-2 did not drastically change 
the MYC-induced expression profile but rather 
amplified it, for example by enhancing the 
down-regulation of KLK3 and NKX3.1 or by 
increasing the induction of RNF187 and DDIT4 
(Supplementary Fig. 6). Interestingly, overexpression 
of MYC in the presence of OSMI-2 led to 
down-regulation of a high number of genes 
(Supplementary Table). We used RT-qPCR to 
validate that induction of MYC in the presence of 
OSMI-2 results in down-regulation of MMP7, 
ZNF812P, GINS2, ASF1B, DTL, and KLK2 (Fig. 4A). 
Pathway enrichment analysis of the genes that were 
down-regulated specifically upon the combination 
treatment identified the cell cycle, and more 
specifically, the transition from G1- to S-Phase, as the 
most significant process (Supplementary Fig. 7A), 
suggesting that OGT might be important for 
MYC-regulated cell cycle progression. 
Next, we used reverse-phase protein array 
technology (RPPA) to test if OGT affects the 
MYC-dependent proteome. We focused on the 
proteins that required OGT activity to be regulated by 
MYC and identified 28 proteins (10% of the total 
detected) (Supplementary Table). Pathway 
enrichment analysis reported a specific point of the 
cell cycle, the G2-M transition, to be enriched for these 
proteins (Supplementary Fig. 7B). MYC-dependent 
expression of these 28 proteins did not strongly 
correlate with mRNA levels (Fig. 4C). On the other 
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hand, for both OSMI-2 on its own and in combination 
with MYC overexpression, we observed a statistically 
significant correlation between mRNA and protein 
levels. We selected two proteins PLK1, and Cyclin B1, 
to validate the RPPA-data using RT-qPCR and 
western blotting. MYC-induced expression of these 
proteins was antagonized by OSMI-2 at the protein 
level but not affected at the mRNA level (Fig. 4D and 
Supplementary Fig. 7C). 
To identify potential mechanisms for OSMI-2 
induced down-regulation of MYC-regulated proteins, 
we turned our attention to the genes that were 
induced when OSMI-2 was combined with MYC 
overexpression. Induction of MYC in the presence of 
OSMI-2 resulted in a 12-fold increased expression of 
the lactotransferrin (LTF)-gene (Fig. 4A). O-GlcNAc, 
MYC, and HCF-1 were all bound to the enhancer of 
the LTF-gene (Supplementary Fig. 8A, B, C). LTF acts 
as a tumor-suppressor through its ability to induce 
the expression of ubiquitin ligases and the protein is 
negatively regulated by OGT [56]. Based on our 
RNA-seq data, we identified and subsequently 
 
 
Figure 4. OGT affects MYC-dependent transcription. The expression of MYC was induced in the LNCaP-MYC cell line by addition of doxycycline (Dox). A) Validation 
of the RNA-seq data using RT-qPCR. Treatment time is 24 hours and OSMI-2 dose 40µM. MMP7, ZNF (=ZNF812P), GINS2, ASF1B, DTL and KLK2 were down-regulated in the 
combination treatment with OSMI-2 and doxycycline (to induce MYC), while LTF, FBX (=FBXO32) and PRKN were up-regulated. Data shown is an average of three biological 
replicates with SEM. Student’s t-test was used to evaluate statistical significance between Dox and Dox+OSMI-2 condition, *<0.05 and **<0.01. B) Cells were treated with Dox 
and 40µM OSMI-2 for 24 hours and analyzed by western blotting. C) Pearson correlation of mRNA and protein expression for the proteins that were induced by 
MYC-overexpression and antagonized by OSMI-2. D) MYC-induced upregulation of PLK1 and Cyclin B1 is antagonized by OSMI-2 (OS2). Cells were treated as indicated and 
samples were analyzed using western blotting. E) Expression of the LTF gene in prostate cancer patient samples. Data was downloaded from 
http://www.betastasis.com/prostate_cancer/taylor_et_al_2010. The mean values with SEM are shown for each group. The significance of the data was evaluated using Student’s 
t-test in comparison to normal samples, *<0.05, **<0.01. F) LNCaP-MYC cells were grown in the absence of androgens for 3 days, treated as indicated for an additional 24 hours, 
protein lysates were collected and western blot was used to detect the indicated proteins. 
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validated that two ubiquitin ligases, FBXO32 and 
PRKN, are induced by OGT inhibition 
(Supplementary Table and Fig. 4A). In order to 
understand the potential clinical relevance of LTF in 
prostate cancer, we evaluated its expression in patient 
samples. Interestingly, LTF is abundantly expressed 
in normal prostate tissue and in low-grade tumors 
(Gleason score<7), but its expression is completely 
shut down in the metastatic tissue (Fig. 4E). 
Taken together, OGT regulates MYC-dependent 
transcription of certain mRNAs involved in the 
control of G1-S transition and additionally promotes 
protein stability of mitotic proteins. MYC-induced 
expression of ubiquitin ligases adds another layer of 
complexity to MYC-dependent regulation of cell 
function; this response will be further characterized in 
future studies. Our data suggest that OGT should be 
especially important for MYC-driven proliferation. 
OGT is required for MYC-dependent 
proliferation of prostate cancer cells in the 
absence of androgens 
MYC is required for the androgen-independent 
proliferation of prostate cancer cells, the major cause 
of disease progression [48, 57]. This can be modeled in 
vitro using the LNCaP-MYC cell line, which requires 
androgens to achieve full growth potential; however, 
MYC-expression can be induced by addition of 
doxycycline and this is sufficient to promote 
androgen-independent proliferation [48, 58]. 
First, we wanted to assess if MYC can promote 
the expression of mitotic proteins in the absence of 
androgens and whether OGT activity is important in 
this setting. We observed an even stronger induction 
of Cyclin B1, and PLK1, when compared to cells 
growing in the presence of androgens (Fig. 4D, F and 
Supplementary Fig. 8D). OSMI-2 treatment almost 
completely antagonized MYC-induced expression of 
Cyclin B1, and PLK1. Overexpression of MYC also 
increased phosphorylation of the marker of mitosis, 
p-H3ser10, and this was decreased by OSMI-2. Of 
note, cells are able to adapt to OSMI-2 treatment by 
increasing the expression of OGT and decreasing the 
expression of OGA, and the OSMI-2 effect on 
total-O-GlcNAc at 24 hours of treatment in the 
absence of androgens is modest. Using siRNAs 
against OGT we confirmed that the MYC-induced 
increase in the expression of Cyclin B1 and PLK1 is 
dependent on OGT (Fig. 5A). 
Second, we used flow cytometry to assess the 
role of OGT in MYC-induced cell cycle progression. 
Androgen-deprivation decreased the number of cells 
in S-Phase by over 50% (Fig. 5B). Overexpression of 
MYC was able to double the number of cells going 
through the S-Phase in the absence of androgens. 
Importantly, OSMI-2 antagonized MYC-induced 
accumulation of cells in the S-Phase. 
We next used viability assays to confirm reports 
that MYC overexpression promotes proliferation of 
prostate cancer cells in the absence of androgens [48, 
57, 58]. Overexpression of MYC increased cell 
viability by 25% in the absence of androgens but did 
not increase viability in the presence of androgens 
(Fig. 5C). The growth-benefit of MYC-overexpression 
was decreased by treatment with OSMI-2 and 
completely antagonized by siRNAs targeting OGT. 
Here we show that the androgen-independent 
growth advantage induced by MYC is dependent on 
OGT. Our data shows that the high expression of 
certain factors at the protein level, even in the absence 
of mRNA elevation, might be important for cancer cell 
proliferation and could be used as biomarkers. To test 
this, we evaluated the predictive value of Cyclin B1 at 
the mRNA and protein levels in prostate cancer 
patients. CCNB1 mRNA is non-significantly 
associated with disease progression (p=0.203), while 
increased protein level expression of Cyclin B1 is 
significantly associated with disease progression 
(p=0.000014; Logrank test, Fig. 5D, E). These results 
highlight the importance of evaluating both mRNA 
and protein level data to understand the relevance 
and predictive value of prognostic markers. 
Taken together, OGT is important for the 
MYC-driven cellular program at two levels: the 
transcription of genes involved in the G1-S transition 
and the stabilization of proteins involved in the G2-M 
transition. This renders high OGT activity 
indispensable for MYC-dependent proliferation of 
prostate cancer cells. 
Discussion 
Mammalian OGT is required for development, 
normal physiological functions of post-mitotic cells 
and proliferation of immortalized cells [33, 59-62]. 
Here, we have shown that OGT regulates 
MYC-dependent transcription and affects levels of 
mitotic proteins in prostate cancer cells. 
In general, the functional role of OGT in the 
regulation of transcription is poorly understood, but 
one of the most prominent O-GlcNAc modified 
proteins is RNA-Pol II itself. Glycosylation of 
RNA-Pol II CTD has been shown to regulate 
pre-initiation complex formation using in vitro assays 
and O-GlcNAc mark is found on the promoters in 
human cell lines as reported here and shown by 
others [12, 13, 44]. In addition, O-GlcNAc is enriched 
on the promoters in Caenorhabditis elegans, but the 
modification is not responsive to nutrients [63]. 
Perturbation of OGT activity in specific cell or organ 
type has prominent effects on transcription and 
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overall physiology of the animal in mouse studies [62, 
64], however, given the high number of OGT-targets, 
it is not possible to attribute these effects directly to 
transcription. We observed that prostate cancer 
super-enhancer (SE) genes are also marked by the 
O-GlcNAc chromatin mark and that OGT inhibition 
decreases the expression of SE-mRNAs (Fig. 2D, E). 
This implies that OGT activity may be particularly 
important for highly transcribed genes. In the future, 
it is important to establish how inhibition of OGT 
affects transcription using GRO- and NET-seq type 
assays. 
We show that inhibition of OGT enhances 
MYC-regulated transcriptional repression of certain 
cell cycle genes, possibly due to disruption of 
MYC-containing protein complexes, albeit the exact 
mechanism(s) for this remain to be determined (Figs. 
3E, 3F and 4A). In addition, we showed that OGT is 
important for MYC-regulated expression of mitotic 
proteins (Figs. 4D, 4F, 5A). Based on these data, we 
propose that the decrease in OGT activity leads to 
suppression of cell cycle program by a dual 
mechanism: at the mRNA level to control initiation of 
the S-Phase and additionally OGT affects the stability 
of proteins involved in mitosis (Figs. 4A and 5A). 
OGT would thereby function as a metabolic rheostat 
and utilize its catalytic activity to halt the cell cycle in 
the absence of sufficient energy and promote 
proliferation when nutrients are abundant. 
Excessive nutrient uptake is detrimental to 
health in general, and obesity has been linked to both 
breast and prostate cancers [65, 66]. A high rate of 
 
Figure 5. OGT is required for MYC-induced proliferation of prostate cancer cells in the absence of androgens. A) OGT knockdown was started at the same 
time as androgen-deprivation, which lasted for 3 days, at which point cells were treated with doxycycline for 24 hours as indicated. Samples were analyzed using western blot. 
Data shown is representative of 2 biological replicates. B) Propidium iodide staining and flow cytometry were used to determine cell cycle distribution after 24 hours treatment 
(cells were first androgen-deprived for 3 days as indicated). OSMI-2 dose was 40 µM. The data shown is an average of three biological replicates with SEM. OSMI-2= OS2; Dox= 
D. C) Viability of cells was assessed using the Cell Titer Glo-reagent after 3 days of treatment. Data shown is an average of three biological replicates with SEM and significance 
was assessed using the Student’s t-test, * < 0.05, **<0.01. OSMI-2 dose was 40µM. OSMI-2= OS2; Dox= D; S=Scrambled; si1 and si2= siOGT1 and siOGT2. D) Correlation 
between increased expression of Cyclin B1 at the mRNA level and progression free survival was evaluated using the prostate adenocarcinoma TCGA-dataset, accessed through 
the cBioPortal for Cancer Genomics [76, 77]. E) Correlation between increased expression of Cyclin B1 at the protein level and progression free survival was evaluated using 
the prostate adenocarcinoma TCGA-dataset, accessed through the cBioPortal for Cancer Genomics [76, 77]. 
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proliferation requires a constant supply of energy, but 
it is becoming increasingly clear that metabolism can 
also directly affect cell fate [3, 9, 67, 68]. It is known 
that glucose feeding stimulates OGT-activity in 
mouse liver and that overexpression of the glucose 
transporter GLUT3 in nonmalignant breast cells leads 
to loss of tissue polarity and activation of 
tumor-promoting pathways [10, 69]. We therefore 
speculate that increased blood glucose, as observed in 
common conditions such as pre-diabetes, which 
affects over 80 million Americans (source: American 
Diabetes Association), could serve as a second hit, and 
be a variation of the genetic ‘2-hit’ hypothesis [14, 70]. 
OGT is essentially required in proliferating cells 
but post-mitotic cells can survive without it, which 
makes the enzyme a prototypical cancer-target [60]. 
OSMI-2 binds to the active site of OGT, and higher 
levels of the OGT’s substrate, UDP-GlcNAc , in 
LNCaP cells than PC3 cells, renders total-O-GlcNAc 
levels less sensitive to this inhibitor (Fig. 1A) [19, 34]. 
AR promotes the expression of the hexosamine 
biosynthetic pathway (HBP) enzymes and prostate 
cancer cells therefore have high levels of 
UDP-GlcNAc [14, 19]. Interestingly, progression to 
lethal, castration-resistant prostate cancer (CRPC) 
leads to a prominent down-regulation of the HBP 
enzymes [71]. The development of CRPC is not 
completely understood, but one of the factors known 
to be able to confer CRPC phenotype is MYC [48, 57, 
72]. In this study, we showed that MYC-driven, 
androgen-independent proliferation of prostate 
cancer cells requires OGT. Based on these data, OGT 
inhibitors could be combined with anti-androgens to 
target the cancer cells that become dependent on 
MYC. 
In conclusion, we show that O-GlcNAc, MYC 
and HCF-1 are found in transcription start sites that 
contain the GFY-motif and that OGT activity is 
required for the robust interaction between MYC and 
HCF-1. Inhibition of OGT-activity impairs MYC’s 
ability to promote androgen-independent 
proliferation. Our work suggests that OGT could be a 
drug-target in MYC-addicted tumors. Identification of 
new actionable targets for cancer-therapy is urgently 
needed, and in the future, it will be important to 
understand potential cancer cell-specific adaptive 
response(s) that are activated in response to OGT 
inhibition. 
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